Blending Bold Strategy with Proven Market Access and Health Economics Expertise to Unlock Asset Value
Herspiegel, a leader in pharmaceutical commercialization services, today announced the acquisition of Decisive Consulting. This strategic expansion unites Decisive’s global market access focused “Rebel Thinking” with Herspiegel’s world-class commercialization services, creating a powerhouse of strategy, evidence, and execution across the product lifecycle.
Known for its bold, creative problem-solving, Decisive Consulting helps life sciences companies challenge convention to drive breakthrough market access. Now united with the recently acquired FIECON’s industry-leading HEOR and HTA expertise and Herspiegel’s proven U.S. market access and commercialization capabilities, the combined set of commercialization services helps clients navigate complexity and seize opportunity from early asset strategy to launch readiness and market optimization. This integrated approach brings together scientific insight, evidence strategy, deep market intuition, and executional precision to ensure brands are built to lead.
“The addition of Decisive Consulting further strengthens our ability to unlock asset value and improve patient access to life-changing therapies. Together, we offer the full spectrum of global market access expertise—from early evidence planning through successful launch and beyond.”
Brent Herspiegel, CEO of Herspiegel
Esther Nzenza, CEO and Founder of Decisive Consulting, will remain with Herspiegel as Senior Partner Global Value and Market Access. Esther will continue in a leadership role to deliver industry-leading strategy and impact for clients seeking to expand access to their innovative treatments across international markets.
“As part of Herspiegel we will be a true powerhouse in Access, HEOR and go to market strategy, scaled and able to cover worldwide markets with fluency and with industry leading capabilities across the areas that we serve.”
Esther Nzenza, Founder of Decisive Consulting
Together with the recent integration of FIECON, Herspiegel and Decisive Consulting will power commercial success to enable access to innovative medicines and improve patient outcomes worldwide.
